Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-cd138 chimeric antigen receptor, coding gene, recombinant expression vector and its construction method and application

A chimeric antigen receptor, chimeric receptor technology, applied in the direction of carrier, antibody medical component, recombinant DNA technology, etc.

Active Publication Date: 2019-07-02
SHANGHAI UNICAR THERAPY BIOPHARM TECH CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It is worth noting that the above differences are only the conclusions obtained from in vitro experiments, and there is no report comparing the second-generation and third-generation CARs in vivo.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-cd138 chimeric antigen receptor, coding gene, recombinant expression vector and its construction method and application
  • Anti-cd138 chimeric antigen receptor, coding gene, recombinant expression vector and its construction method and application
  • Anti-cd138 chimeric antigen receptor, coding gene, recombinant expression vector and its construction method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0079] Example 1 Construction of recombinant lentiviral vector

[0080] 1. Materials

[0081] 1. The lentiviral backbone plasmid pLenti-3G ​​basic, the lentiviral packaging plasmids pPac-GP, pPac-R and the membrane protein plasmid pEnv-G, HEK293T / 17 cells, and homologous recombination enzyme were supplied by Shiao (Shanghai) Biomedical Technology Co., Ltd. supply;

[0082] 2. Primers: According to the principles of primer design, the primers required for amplifying DNA fragments and target sites are designed. The primers are synthesized by Shanghai Biological Company, specifically:

[0083] EF1α-F: 5'-attcaaaattttatcgatgctccggtgcccgtcagt-3' (SEQ ID NO. 26)

[0084] EF1α-R: 5'-TCACGACACCTGAAATGGAAGA-3' (SEQ ID NO.27)

[0085] CD8leader-F: 5'-ggtgtcgtgaggatccgccaccatggccttaccagtgaccgc-3'

[0086] (SEQ ID NO. 28)

[0087] CD8leader-R: 5'-GTGTCATCTGGATGTCCGGCCTGGCGGCGTG-3' (SEQ ID NO.29)

[0088] VL-F: 5'-ccacgccgccaggccggacatccagatgacccagagca-3' (SEQ ID NO.30)

[0089] VL-...

Embodiment 2

[0179] Example 2 Concentration and detection of recombinant lentiviral vector

[0180] Purify the recombinant lentiviral vector by ultracentrifugation;

[0181] (1) Divide the collected supernatant into 50ml centrifuge tubes, centrifuge at 500g room temperature for 10min, and remove cells and large debris;

[0182] (2) Filter the supernatant with a 0.22 μm-0.8 μm filter;

[0183] (3) Take 6 Hitachi 40PA ultracentrifuge tubes, spray 70% ethanol on the surface to sterilize them, put them on a clean table and irradiate them with ultraviolet light for 30 minutes to sterilize them. It can also be sterilized by high temperature and moist heat;

[0184] (4) Aliquot 32ml of the cell supernatant sample processed in step 2 into a centrifuge tube;

[0185] (5) Cover the metal cover, balance the centrifuge tube together with the metal cover, and adjust with 1XPBS to make the weight deviation within 0.02g;

[0186] (6) Place the balanced centrifuge tubes symmetrically in the ultracentr...

Embodiment 3

[0262] Example 3 Functional detection of recombinant lentiviral vectors lvCAR138-CLA, lvCAR138-CLB, lvCAR138-OLC

[0263] 1. Cell-level expression detection of CAR gene:

[0264] (1) After infecting PBMC cells with recombinant lentiviral vectors lvCAR138-CLA, lvCAR138-CLB, and lvCAR138-OLC, collect the cells and use RT-PCR to detect CAR mRNA transcription levels to verify the expression of CAR genes. If the CAR mRNA transcription levels increase, then It shows that the transcription level expression of CAR gene is successful;

[0265] (2) After infecting PBMC cells with recombinant lentiviral vectors lvCAR138-CLA, lvCAR138-CLB, and lvCAR138-OLC, collect the cells and detect the expression level of CAR protein by western blot to verify the expression of CAR gene. If the expression level of CAR protein increases, then It shows that the translation level expression of CAR gene is successful;

[0266] (3) Infect the cells with lvCAR138-CLA, lvCAR138-CLB, lvCAR138-OLC and the con...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an anti-CD138 chimeric antigen receptor, a coding gene, a recombinant expression vector and a construction method and an application of the recombinant expression vector. The anti-CD138 chimeric antigen receptor comprises a CD8leader chimeric receptor signal peptide, a light chain VH of the CD138 single-chain antibody, an Optimal Linker C, a heavy chain VL of a CD138 single-chain antibody, a CD8Hinge chimeric receptor hinge, a CD8Transmembrane chimeric receptor transmembrane domain, a CD137 chimeric receptor co-stimulation factor and a TCR chimeric receptor T-cell activation domain, which are serially connected in sequence. In addition, the invention discloses the coding gene of the anti-CD138 chimeric antigen receptor, the recombinant expression vector and the construction method and the application of the recombinant expression vector. According to the anti-CD138 chimeric antigen receptor, the secretion of cell factors and the in vitro killing effect of CAR-T (Chimeric Antigen Receptor T-Cell Immunotherapy) cells can be remarkably improved, and the clinical treatment effect is outstanding.

Description

technical field [0001] The invention belongs to the technical field of tumor immunotherapy, and specifically relates to an anti-CD138 chimeric antigen receptor, a coding gene, a recombinant expression vector (especially a CAR-T transgene vector based on a replication-defective recombinant lentivirus) and a construction method thereof and apply. Background technique [0002] The theoretical basis of tumor immunotherapy is that the immune system has the ability to recognize tumor-associated antigens and regulate the body's ability to attack tumor cells (highly specific cytolysis). This biological process is complex and is still under investigation. In the 1990s, several scientific research groups have discovered tumor antigens (tμmor antigens), and T lymphocytes can recognize these tumor antigens in a major histocompatibility complex (MHC)-dependent manner. [0003] Tumor immunotherapy is generally divided into two categories, nonspecific immunity and specific immunity. Non...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K19/00C12N15/62C12N15/867C12N15/65C12N5/10A61K35/17A61P35/00
CPCA61K35/17A61K2039/5156A61K2039/5158C07K14/7051C07K14/70517C07K14/70521C07K14/70596C07K16/2896C07K16/30C07K2317/51C07K2317/515C07K2317/622C07K2319/02C07K2319/03C07K2319/33C07K2319/74C12N5/0636C12N15/65C12N15/86C12N2510/00C12N2740/15043C12N2800/107
Inventor 祁伟俞磊
Owner SHANGHAI UNICAR THERAPY BIOPHARM TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com